Jiangsu Aidea Pharmaceutical Full Year 2023 Earnings: CN¥0.18 loss per share (vs CN¥0.30 loss in FY 2022)
Jiangsu Aidea Pharmaceutical (SHSE:688488) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥411.4m (up 68% from FY 2022).
- Net loss: CN¥76.1m (loss narrowed by 39% from FY 2022).
- CN¥0.18 loss per share (improved from CN¥0.30 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Jiangsu Aidea Pharmaceutical shares are down 12% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Jiangsu Aidea Pharmaceutical you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688488
Jiangsu Aidea Pharmaceutical
Develops, produces, and sells pharmaceutical products.
Excellent balance sheet with limited growth.
